The Role of FBXW7 in Gynecologic Malignancies

Riccardo Di Fiore; Sherif Suleiman; Rosa Drago-Ferrante; Yashwanth Subbannayya; Sarah Suleiman; Mariela Vasileva-Slaveva; Angel Yordanov; Francesca Pentimalli; Antonio Giordano; Jean Calleja-Agius

doi:10.3390/cells12101415

Back

The Role of FBXW7 in Gynecologic Malignancies

Review

Peer reviewed

The Role of FBXW7 in Gynecologic Malignancies

Riccardo Di Fiore, Sherif Suleiman, Rosa Drago-Ferrante, Yashwanth Subbannayya, Sarah Suleiman, Mariela Vasileva-Slaveva, Angel Yordanov, Francesca Pentimalli, Antonio Giordano and Jean Calleja-Agius

Cells, Vol.12(10), 1415

17/05/2023

DOI: https://doi.org/10.3390/cells12101415

Abstract

epigenetic

FBXW7

gynecologic cancers

LncRNAs

miRNAs

mutations

Review

target therapy

ubiquitin-proteasome system

The F-Box and WD Repeat Domain Containing 7 (FBXW7) protein has been shown to regulate cellular growth and act as a tumor suppressor. This protein, also known as FBW7, hCDC4, SEL10 or hAGO, is encoded by the gene FBXW7. It is a crucial component of the Skp1-Cullin1-F-box (SCF) complex, which is a ubiquitin ligase. This complex aids in the degradation of many oncoproteins, such as cyclin E, c-JUN, c-MYC, NOTCH, and MCL1, via the ubiquitin-proteasome system (UPS). The FBXW7 gene is commonly mutated or deleted in numerous types of cancer, including gynecologic cancers (GCs). Such FBXW7 mutations are linked to a poor prognosis due to increased treatment resistance. Hence, detection of the FBXW7 mutation may possibly be an appropriate diagnostic and prognostic biomarker that plays a central role in determining suitable individualized management. Recent studies also suggest that, under specific circumstances, FBXW7 may act as an oncogene. There is mounting evidence indicating that the aberrant expression of FBXW7 is involved in the development of GCs. The aim of this review is to give an update on the role of FBXW7 as a potential biomarker and also as a therapeutic target for novel treatments, particularly in the management of GCs. (This article belongs to the Special Issue Biomarkers for Diagnosis and Treatment of Gynecologic Neoplasms)

Metrics

13 Record Views

3 Times Cited - Web of Science

See more details

Details

Title: The Role of FBXW7 in Gynecologic Malignancies
Creators: Riccardo Di Fiore - Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA BioDNA Laboratories, Malta Life Sciences Park, SGN 3000 San Gwann, Malta School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK Whipps Cross Hospital, Barts Health NHS Trust, Leytonstone, London E11 1NR, UK Department of Breast Surgery, “Dr. Shterev” Hospital, 1330 Sofia, Bulgaria Research Institute, Medical University Pleven, 5800 Pleven, Bulgaria Bulgarian Breast and Gynecological Cancer Association, 1784 Sofia, Bulgaria Department of Gynecological Oncology, Medical University Pleven, 5800 Pleven, Bulgaria Department of Medicine and Surgery, LUM University “Giuseppe DeGennaro”, 70010 Casamassima, Italy Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
Sherif Suleiman - Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA BioDNA Laboratories, Malta Life Sciences Park, SGN 3000 San Gwann, Malta School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK Whipps Cross Hospital, Barts Health NHS Trust, Leytonstone, London E11 1NR, UK Department of Breast Surgery, “Dr. Shterev” Hospital, 1330 Sofia, Bulgaria Research Institute, Medical University Pleven, 5800 Pleven, Bulgaria Bulgarian Breast and Gynecological Cancer Association, 1784 Sofia, Bulgaria Department of Gynecological Oncology, Medical University Pleven, 5800 Pleven, Bulgaria Department of Medicine and Surgery, LUM University “Giuseppe DeGennaro”, 70010 Casamassima, Italy Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
Rosa Drago-Ferrante - Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA BioDNA Laboratories, Malta Life Sciences Park, SGN 3000 San Gwann, Malta School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK Whipps Cross Hospital, Barts Health NHS Trust, Leytonstone, London E11 1NR, UK Department of Breast Surgery, “Dr. Shterev” Hospital, 1330 Sofia, Bulgaria Research Institute, Medical University Pleven, 5800 Pleven, Bulgaria Bulgarian Breast and Gynecological Cancer Association, 1784 Sofia, Bulgaria Department of Gynecological Oncology, Medical University Pleven, 5800 Pleven, Bulgaria Department of Medicine and Surgery, LUM University “Giuseppe DeGennaro”, 70010 Casamassima, Italy Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
Yashwanth Subbannayya
Sarah Suleiman - Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA BioDNA Laboratories, Malta Life Sciences Park, SGN 3000 San Gwann, Malta School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK Whipps Cross Hospital, Barts Health NHS Trust, Leytonstone, London E11 1NR, UK Department of Breast Surgery, “Dr. Shterev” Hospital, 1330 Sofia, Bulgaria Research Institute, Medical University Pleven, 5800 Pleven, Bulgaria Bulgarian Breast and Gynecological Cancer Association, 1784 Sofia, Bulgaria Department of Gynecological Oncology, Medical University Pleven, 5800 Pleven, Bulgaria Department of Medicine and Surgery, LUM University “Giuseppe DeGennaro”, 70010 Casamassima, Italy Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
Mariela Vasileva-Slaveva - Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA BioDNA Laboratories, Malta Life Sciences Park, SGN 3000 San Gwann, Malta School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK Whipps Cross Hospital, Barts Health NHS Trust, Leytonstone, London E11 1NR, UK Department of Breast Surgery, “Dr. Shterev” Hospital, 1330 Sofia, Bulgaria Research Institute, Medical University Pleven, 5800 Pleven, Bulgaria Bulgarian Breast and Gynecological Cancer Association, 1784 Sofia, Bulgaria Department of Gynecological Oncology, Medical University Pleven, 5800 Pleven, Bulgaria Department of Medicine and Surgery, LUM University “Giuseppe DeGennaro”, 70010 Casamassima, Italy Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
Angel Yordanov - Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA BioDNA Laboratories, Malta Life Sciences Park, SGN 3000 San Gwann, Malta School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK Whipps Cross Hospital, Barts Health NHS Trust, Leytonstone, London E11 1NR, UK Department of Breast Surgery, “Dr. Shterev” Hospital, 1330 Sofia, Bulgaria Research Institute, Medical University Pleven, 5800 Pleven, Bulgaria Bulgarian Breast and Gynecological Cancer Association, 1784 Sofia, Bulgaria Department of Gynecological Oncology, Medical University Pleven, 5800 Pleven, Bulgaria Department of Medicine and Surgery, LUM University “Giuseppe DeGennaro”, 70010 Casamassima, Italy Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
Francesca Pentimalli - Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA BioDNA Laboratories, Malta Life Sciences Park, SGN 3000 San Gwann, Malta School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK Whipps Cross Hospital, Barts Health NHS Trust, Leytonstone, London E11 1NR, UK Department of Breast Surgery, “Dr. Shterev” Hospital, 1330 Sofia, Bulgaria Research Institute, Medical University Pleven, 5800 Pleven, Bulgaria Bulgarian Breast and Gynecological Cancer Association, 1784 Sofia, Bulgaria Department of Gynecological Oncology, Medical University Pleven, 5800 Pleven, Bulgaria Department of Medicine and Surgery, LUM University “Giuseppe DeGennaro”, 70010 Casamassima, Italy Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
Antonio Giordano - Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA BioDNA Laboratories, Malta Life Sciences Park, SGN 3000 San Gwann, Malta School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK Whipps Cross Hospital, Barts Health NHS Trust, Leytonstone, London E11 1NR, UK Department of Breast Surgery, “Dr. Shterev” Hospital, 1330 Sofia, Bulgaria Research Institute, Medical University Pleven, 5800 Pleven, Bulgaria Bulgarian Breast and Gynecological Cancer Association, 1784 Sofia, Bulgaria Department of Gynecological Oncology, Medical University Pleven, 5800 Pleven, Bulgaria Department of Medicine and Surgery, LUM University “Giuseppe DeGennaro”, 70010 Casamassima, Italy Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
Jean Calleja-Agius - Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA BioDNA Laboratories, Malta Life Sciences Park, SGN 3000 San Gwann, Malta School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK Whipps Cross Hospital, Barts Health NHS Trust, Leytonstone, London E11 1NR, UK Department of Breast Surgery, “Dr. Shterev” Hospital, 1330 Sofia, Bulgaria Research Institute, Medical University Pleven, 5800 Pleven, Bulgaria Bulgarian Breast and Gynecological Cancer Association, 1784 Sofia, Bulgaria Department of Gynecological Oncology, Medical University Pleven, 5800 Pleven, Bulgaria Department of Medicine and Surgery, LUM University “Giuseppe DeGennaro”, 70010 Casamassima, Italy Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
Publication Details: Cells, Vol.12(10), 1415
Publisher: MDPI
Date published: 17/05/2023
Date accepted: 15/05/2023
Grant note: This paper is based upon work from COST Action CA18117—European network for Gynaecological Rare Cancer research: From Concept to Cure (GYNOCARE), supported by the European Co-operation in Science and Technology (COST). COST is a funding agency for research and innovation networks. COST actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, careers, and innovation (www.cost.eu accessed on 24 April 2023). R.D.F., S.S. (Sherif Suleiman), R.D.-F., Y.S., M.V.-S., A.Y., F.P., A.G., and J.C.-A. are action management committee members and/or form part of Working Groups 1–5, and J.C.-A. is the chairperson of this action.
Identifiers: 99764364402346
Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Academic Unit: School of Biosciences
Language: English
Resource Type: Review
SDG (Scopus 2023): SDG 3

The Role of FBXW7 in Gynecologic Malignancies

Abstract

Metrics

Details

Usage Policy